DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Semaglutide reduces alcohol craving and intake in early trials. Patients on GLP-1s frequently report spontaneous reductions in drinking that match the mechanism.
ATTAIN-1 (Phase 2, 2024) showed semaglutide reduced heavy drinking days by ~30% versus placebo at 9 weeks in patients with alcohol use disorder. Multiple observational reports confirm the effect in non-AUD patients on GLP-1s for weight loss.
Novo Nordisk, NIH, addiction medicine specialists. Phase 3 trials enrolling. Some addiction-medicine clinicians prescribe off-label for refractory AUD when standard therapy fails.
Not first-line. Naltrexone, acamprosate, and counseling remain standard of care. Off-label GLP-1 use should be coordinated with addiction medicine. Insurance approval is rare.
The most-evidenced off-label use. If you have AUD plus obesity, the case for Wegovy or Zepbound is strong. If AUD alone, wait for Phase 3 data.
Editorial summary. Off-label use is legal but not FDA-evaluated. Insurance typically does not cover off-label prescriptions. Not medical advice.